One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Bio-Techne Corporation logo
Bio-Techne Corporation TECH
$ 72.57 0.07%
report update icon

Quarterly report 2026-Q4
added 08-24-2026

Bio-Techne Corporation Cash Flow 2026-2008 | TECH

Brief overview of Bio-Techne Corporation's cash flow quality

Cash flows are assessed across five available annual periods spanning 2021 to 2025.

Operating cash flow lost 18.3%, moving from $352.2 million to $287.6 million. This is a negative signal for internal funding.

Operating cash flow was positive in all five observations, adding repeatability to the cash profile.

Across five periods, operating cash flow equaled about 1.62x of cumulative net income. Earnings were strongly backed by cash.

Operating cash margin decreased to 23.6% from 37.8% initially. The quality of receipts deteriorated.

Estimated working capital increased by $138.3 million, equal to 11.3% of latest revenue. More cash became tied up in receivables and inventory.

Overall picture

Bio-Techne Corporation retains acceptable cash resilience. Future assessment depends on cash margin, capex and debt trends.

Annual Cash Flow Bio-Techne Corporation

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Operating Cash Flow

292 M 288 M 299 M 254 M 325 M 352 M 205 M 182 M 170 M 144 M 144 M - - 124 M 127 M 127 M 111 M 111 M -

Depreciation & Amortization

97.4 M 110 M 112 M 107 M 101 M 87.7 M 82.7 M 78.2 M 64.5 M 60 M 42.8 M 37.2 M 19.2 M 12.3 M 12.5 M 8.7 M 8.13 M 7.77 M -

Accounts Payables

26.7 M 25.3 M 38 M 25.7 M 33.9 M 29.4 M 23.1 M 16.2 M 18.5 M 16.9 M 20.7 M 13.4 M 9.65 M 6.24 M 6.29 M 5.21 M 5.23 M - -

Accounts Receivables

217 M 207 M 241 M 218 M 195 M 145 M 123 M 137 M 120 M 117 M 93.4 M 70 M 47.9 M 38.2 M 35.7 M 35.9 M 30.8 M - -

Total Inventories

196 M 189 M 180 M 172 M 141 M 117 M 103 M 91 M 85.6 M 60.2 M 57.1 M 49.6 M 38.8 M 34.9 M 38.3 M 44.9 M 13.7 M - -

All numbers in USD currency

Quarterly Cash Flow Bio-Techne Corporation

2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- 197 M 110 M 27.6 M - 27.6 M - - - 63.9 M - - - 59.4 M - - - 56.1 M 120 M - - 48.4 M 149 M - - 66 M 155 M 66 M - 40.5 M 111 M - - 39.4 M 86 M 39.4 M - 44.7 M 83.9 M 44.7 M - - - - - - - - - - - - - 32.6 M 63.9 M - - 29.3 M 60.6 M 29.3 M - 34.4 M 54.9 M 34.4 M

Depreciation & Amortization

- 73.2 M 49 M 24.3 M 15.5 M 24.3 M - - 18.9 M 28.1 M - - - 28.5 M - - - 26.6 M 53.3 M 55.7 M 37.3 M 24.7 M 49.8 M - - 21.1 M 42 M 21.1 M - 20.1 M 40.6 M - - 19.1 M 38.9 M 19.1 M - 15.4 M 31 M 15.4 M - 13.6 M 29.2 M - 7.36 M 10.7 M 21.3 M 10.7 M 6.86 M 8.56 M 18.5 M 8.56 M 2.59 M 4.09 M 8.95 M 4.09 M - 3.1 M 6.28 M 3.1 M - 3.14 M 6.31 M 3.14 M

Accounts Payables

25.3 M 23.5 M 26.3 M 30.2 M 26.3 M 30.2 M 25.3 M 31.6 M 33.1 M 31.6 M 38 M 28.9 M 31.5 M 28.1 M 25.7 M 27.1 M 24.1 M 30.5 M 33.9 M 30.9 M 26.8 M 25.6 M 29.4 M 29.4 M 24.3 M 27.2 M 23.1 M 23.1 M 19.1 M 14.1 M 16.2 M 16.2 M 16 M 18.3 M 18.5 M 18.5 M 11.3 M 15.1 M 16.9 M 16.9 M 12.9 M 14.2 M 20.7 M 20.7 M 10.4 M 13.2 M 13.4 M 13.4 M 13.1 M 13.6 M 9.65 M 9.65 M 7.16 M 6.66 M 6.24 M 6.24 M 6.47 M 6.54 M 6.29 M 6.29 M 5.91 M 5.73 M 5.21 M 5.21 M

Accounts Receivables

207 M 215 M 185 M 184 M 185 M 184 M 207 M 237 M 218 M 224 M 241 M 228 M 207 M 205 M 218 M 216 M 185 M 174 M 195 M 202 M 153 M 148 M 145 M 145 M 128 M 123 M 123 M 123 M 112 M 123 M 137 M 137 M 113 M 115 M 120 M 120 M 98.5 M 107 M 117 M 117 M 104 M 110 M 93.4 M 93.4 M 66.1 M 70.9 M 70 M 70 M 57.2 M 60.9 M 55 M 47.9 M 38.3 M 42.2 M 38.2 M 38.2 M 32.2 M 35.1 M 35.7 M 35.7 M 32.4 M 34.1 M 35.9 M 35.9 M

Total Inventories

189 M 201 M 205 M 203 M 205 M 203 M 189 M 191 M 188 M 185 M 180 M 179 M 181 M 186 M 172 M 169 M 160 M 150 M 141 M 128 M 122 M 117 M 117 M 117 M 107 M 106 M 103 M 103 M 95.4 M 90.9 M 91 M 91 M 90.9 M 90.9 M 85.6 M 85.6 M 68.3 M 66.5 M 85.6 M 60.2 M 66.1 M 70.5 M 57.1 M 57.1 M 58.7 M 59 M 49.6 M 49.6 M 52.8 M 52.2 M 38.8 M 38.8 M 40 M 40 M 34.9 M 34.9 M 37.6 M 38.4 M 38.3 M 38.3 M 41 M 42.1 M 44.9 M 44.9 M

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Bio-Techne Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
- 1.3 % $ 27.7 M franceFrance
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
- - $ 5.72 M chinaChina
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
$ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
- - $ 3.85 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
ADiTx Therapeutics ADiTx Therapeutics
ADTX
- - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
- - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Path Holdings Bio-Path Holdings
BPTH
- - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA